$RSLS News

Last published 1y ago

1y agoRSLSVyome closes Merger Transaction, Will Trade on Nasdaq as HIND TomorrowBusiness WireVyome Therapeutics, Inc. ("Vyome"), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the
1y agoRSLSVyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDBusiness WireEffective as of Commencement of Trading on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market
1y agoRSLSVyome Announces New Board of Directors with Deep MIT and AI TiesBusiness WireHeavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting
1y agoRSLSReShape Lifesciences Announces Shareholder Approval of Merger with Vyome TherapeuticsBusiness WireExpected to be Effective as of Commencement of Trading on August 15, 2025 ReShape Lifesciences® (NASDAQ:RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the
1y agoRSLSReShape Lifesciences® Announces Partial Adjournment of Special Meeting of StockholdersGlobeNewswirePartial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by
1y agoRSLSReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon SummitGlobeNewswireIRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural
1y agoRSLSReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025GlobeNewswireBoard of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling
1y agoRSLSReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon SystemGlobeNewswireIRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S.
1y agoRSLSReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementGlobeNewswireIRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it
1y agoRSLSReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad MedisysGlobeNewswireReduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE
1y agoRSLSReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation TechnologyGlobeNewswireIRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a
1y agoRSLSReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD MarketsGlobeNewswireIRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S.
1y agoRSLSReShape Lifesciences® Announces Pricing of $2.6 Million Public OfferingGlobeNewswireIRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® ("ReShape" or the "Company") (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the
1y agoRSLSReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product PortfolioGlobeNewswireIRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management
1y agoRSLSReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate UpdateGlobeNewswireIRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first
1y agoRSLSReShape Lifesciences Announces 1-for-25 Reverse Stock SplitGlobeNewswireIRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has
1y agoRSLSReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation SymposiumGlobeNewswireVagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional
1y agoRSLSReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon SystemGlobeNewswireIRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a
1y agoRSLSReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation TechnologyGlobeNewswireVagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard
1y agoRSLSReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. MarketGlobeNewswireIRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement
1y agoRSLSReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSignificant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Remain
1y agoRSLSReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation TechnologyGlobeNewswireIRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a
1y agoRSLSReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEXGlobeNewswireIRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed a
1y agoRSLSReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public OfferingGlobeNewswireIRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® ("ReShape" or the "Company") (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the
1y agoRSLSReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation TechnologyGlobeNewswireIRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a
1y agoRSLSReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad MedisysGlobeNewswireIRVINE, Calif. and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, and Vyome Therapeutics, Inc.
1y agoRSLSReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoRSLSReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate UpdateGlobeNewswireRevenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023 Significant Reduction in Overall
1y agoRSLSReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateGlobeNewswireIRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial
1y agoRSLSReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEXGlobeNewswireIRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada has updated
2y agoRSLSReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ TechnologyGlobeNewswireIRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded an
2y agoRSLSReShape Lifesciences Announces 1-for-58 Reverse Stock SplitGlobeNewswireIRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has
2y agoRSLSReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoRSLSReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate UpdateGlobeNewswireEntered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared to the First Half of
2y agoRSLSReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate UpdateGlobeNewswireIRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial
2y agoBFAC FXNC RSLS TLRSKuehn Law Encourages BFAC, TLRS, RSLS, and FXNC Investors to Contact Law FirmGlobeNewswireNEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoRSLSVyome to go public and trade on the Nasdaq Capital Market under the ticker symbol "HIND"GlobeNewswireCAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential,
2y agoRSLSReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad MedisysGlobeNewswireReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to Affiliate of Biorad Medisys
2y agoRSLSReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoRSLSReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate UpdateGlobeNewswireCommercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of
2y agoRSLSReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateGlobeNewswireIRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial
2y agoRSLSReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon SystemGlobeNewswireIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a
2y agoRSLSReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEXGlobeNewswire2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE, Calif., March 04,
2y agoRSLSReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEXGlobeNewswireIRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric surgical fellows
2y agoRSLSReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership AlternativesGlobeNewswireIRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group
2y agoRSLSReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEXGlobeNewswireFLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led
2y agoRSLSReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross ProceedsGlobeNewswireIRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a
3y agoRSLSReShape Lifesciences Inc. (RSLS) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoRSLSReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction PlanGlobeNewswireThird Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To Reduce Operating Expenses In 2024 by Over 40% Compared to 2023 Conference Call to be Held at 5:00 pm ET Today
3y agoRSLSReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate UpdateGlobeNewswireIRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial